Rifabutin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nontuberculous Mycobacterial Infections
Conditions
Nontuberculous Mycobacterial Infections
Trial Timeline
Jun 1, 1984 → May 18, 2017
NCT ID
NCT03164291About Rifabutin
Rifabutin is a phase 3 stage product being developed by Pfizer for Nontuberculous Mycobacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03164291. Target conditions include Nontuberculous Mycobacterial Infections.
What happened to similar drugs?
0 of 3 similar drugs in Nontuberculous Mycobacterial Infections were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00810446 | Pre-clinical | Completed |
| NCT00810407 | Pre-clinical | Completed |
| NCT03164291 | Phase 3 | Completed |
Competing Products
8 competing products in Nontuberculous Mycobacterial Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ALIS + Azithromycin + Ethambutol + ELC | Insmed | Phase 3 | 37 |
| ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS) | Insmed | Phase 3 | 37 |
| LAI plus multi-drug regimen | Insmed | Phase 2 | 32 |
| Liposomal amikacin for inhalation (LAI) + placebo | Insmed | Phase 2 | 32 |
| LAI (Liposomal Amikacin for Inhalation) 590 mg | Insmed | Phase 3 | 37 |
| Molgramostim nebulizer solution | Savara | Phase 2 | 21 |
| Inhaled molgramostim + Antimycobacterial regimen | Savara | Phase 2 | 29 |
| Placebo + SPR720 500 mg + SPR720 1000 mg | Spero Therapeutics | Phase 2 | 25 |